{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:36:02Z","timestamp":1793050562983,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007638","name":"Kidney Foundation, Japan","doi-asserted-by":"publisher","award":["JKFB 21-14"],"award-info":[{"award-number":["JKFB 21-14"]}],"id":[{"id":"10.13039\/501100007638","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche Diagnostics K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-07981-z","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:58:38Z","timestamp":1784224718000},"page":"2465-2473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum activin A and bone metabolism in patients undergoing hemodialysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Yosuke","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-4507","authenticated-orcid":false,"given":"Hirotaka","family":"Komaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"7981_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-005-1903-7","volume":"16","author":"L Dukas","year":"2005","unstructured":"Dukas L, Schacht E, St\u00e4helin HB (2005) In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml\/min is a risk factor for falls and fractures. Osteoporos Int 16:1683\u20131690. https:\/\/doi.org\/10.1007\/s00198-005-1903-7","journal-title":"Osteoporos Int"},{"key":"7981_CR2","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1681\/ASN.2005111194","volume":"17","author":"TL Nickolas","year":"2006","unstructured":"Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223\u20133232. https:\/\/doi.org\/10.1681\/ASN.2005111194","journal-title":"J Am Soc Nephrol"},{"key":"7981_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358\u20131366. https:\/\/doi.org\/10.1038\/sj.ki.5001754","journal-title":"Kidney Int"},{"key":"7981_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00774-012-0411-z","volume":"31","author":"M Wakasugi","year":"2013","unstructured":"Wakasugi M, Kazama JJ, Taniguchi M et al (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31:315\u2013321. https:\/\/doi.org\/10.1007\/s00774-012-0411-z","journal-title":"J Bone Miner Metab"},{"key":"7981_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ki.2013.279","volume":"85","author":"F Tentori","year":"2014","unstructured":"Tentori F, McCullough K, Kilpatrick RD et al (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166\u2013173. https:\/\/doi.org\/10.1038\/ki.2013.279","journal-title":"Kidney Int"},{"key":"7981_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1\u2013S130. https:\/\/doi.org\/10.1038\/ki.2009.188","journal-title":"Kidney Int Suppl"},{"key":"7981_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67:559\u2013566. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.023","journal-title":"Am J Kidney Dis"},{"key":"7981_CR8","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1681\/ASN.2017050584","volume":"29","author":"S Salam","year":"2018","unstructured":"Salam S, Gallagher O, Gossiel F et al (2018) Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 29:1557\u20131565. https:\/\/doi.org\/10.1681\/ASN.2017050584","journal-title":"J Am Soc Nephrol"},{"key":"7981_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1152\/physrev.00002.2018","volume":"99","author":"E Bloise","year":"2019","unstructured":"Bloise E, Ciarmela P, Dela Cruz C et al (2019) Activin A in mammalian physiology. Physiol Rev 99:739\u2013780. https:\/\/doi.org\/10.1152\/physrev.00002.2018","journal-title":"Physiol Rev"},{"key":"7981_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jcb.10613","volume":"90","author":"T Sugatani","year":"2003","unstructured":"Sugatani T, Alvarez UM, Hruska KA (2003) Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 90:59\u201367. https:\/\/doi.org\/10.1002\/jcb.10613","journal-title":"J Cell Biochem"},{"key":"7981_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.kint.2016.07.039","volume":"91","author":"T Sugatani","year":"2017","unstructured":"Sugatani T, Agapova OA, Fang Y et al (2017) Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney Int 91:86\u201395. https:\/\/doi.org\/10.1016\/j.kint.2016.07.039","journal-title":"Kidney Int"},{"key":"7981_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.kint.2017.06.016","volume":"93","author":"MJ Williams","year":"2018","unstructured":"Williams MJ, Sugatani T, Agapova OA et al (2018) The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int 93:147\u2013158. https:\/\/doi.org\/10.1016\/j.kint.2017.06.016","journal-title":"Kidney Int"},{"key":"7981_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5414\/CN109650","volume":"91","author":"F Lima","year":"2019","unstructured":"Lima F, Mawad H, El-Husseini AA et al (2019) Serum bone markers in ROD patients across the spectrum of decreases in GFR: activin A increases before all other markers. Clin Nephrol 91:222\u2013230. https:\/\/doi.org\/10.5414\/CN109650","journal-title":"Clin Nephrol"},{"key":"7981_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000720","volume":"7","author":"X Bian","year":"2019","unstructured":"Bian X, Griffin TP, Zhu X et al (2019) Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy. BMJ Open Diabetes Res Care 7:e000720. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000720","journal-title":"BMJ Open Diabetes Res Care"},{"key":"7981_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135821","volume":"131","author":"F Solagna","year":"2021","unstructured":"Solagna F, Tezze C, Lindenmeyer MT et al (2021) Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs. J Clin Invest 131:e135821. https:\/\/doi.org\/10.1172\/JCI135821","journal-title":"J Clin Invest"},{"key":"7981_CR16","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/ndt\/gfac136","volume":"37","author":"S Bataille","year":"2022","unstructured":"Bataille S, Dou L, Bartoli M et al (2022) Mechanisms of myostatin and activin A accumulation in chronic kidney disease. Nephrol Dial Transplant 37:1249\u20131260. https:\/\/doi.org\/10.1093\/ndt\/gfac136","journal-title":"Nephrol Dial Transplant"},{"key":"7981_CR17","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1210\/clinem\/dgab623","volume":"107","author":"Y Nakagawa","year":"2022","unstructured":"Nakagawa Y, Komaba H, Hamano N et al (2022) Interrelationships between sclerostin, secondary hyperparathyroidism, and bone metabolism in patients on hemodialysis. J Clin Endocrinol Metab 107:e95\u2013e105. https:\/\/doi.org\/10.1210\/clinem\/dgab623","journal-title":"J Clin Endocrinol Metab"},{"key":"7981_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.kint.2020.02.035","volume":"98","author":"Y Nakagawa","year":"2020","unstructured":"Nakagawa Y, Komaba H, Hamano N et al (2020) Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis. Kidney Int 98:970\u2013978. https:\/\/doi.org\/10.1016\/j.kint.2020.02.035","journal-title":"Kidney Int"},{"key":"7981_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","volume":"4","author":"RB Payne","year":"1973","unstructured":"Payne RB, Little AJ, Williams RB et al (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643\u2013646. https:\/\/doi.org\/10.1136\/bmj.4.5893.643","journal-title":"Br Med J"},{"key":"7981_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1515\/cclm-2024-1148","volume":"63","author":"G Lombardi","year":"2024","unstructured":"Lombardi G, J\u00f8rgensen NR, Harvey NC et al (2024) Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone Metabolism. Clin Chem Lab Med 63:704\u2013711. https:\/\/doi.org\/10.1515\/cclm-2024-1148","journal-title":"Clin Chem Lab Med"},{"key":"7981_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000536198","volume":"55","author":"HY Jung","year":"2024","unstructured":"Jung HY, Ryu JH, Kim MG et al (2024) Association of serum activin levels with allograft outcomes in patients with kidney transplant: results from the KNOW-KT. Am J Nephrol 55:245\u2013254. https:\/\/doi.org\/10.1159\/000536198","journal-title":"Am J Nephrol"},{"key":"7981_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23564-3","volume":"8","author":"S Takahashi","year":"2018","unstructured":"Takahashi S, Nakasatomi M, Takei Y et al (2018) Identification of urinary activin A as a novel biomarker reflecting the severity of acute kidney injury. Sci Rep 8:5176. https:\/\/doi.org\/10.1038\/s41598-018-23564-3","journal-title":"Sci Rep"},{"key":"7981_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/diagnostics12030661","volume":"12","author":"I Nagayama","year":"2022","unstructured":"Nagayama I, Maeshima A, Nagata D (2022) Urinary activin A: a novel biomarker for human acute kidney injury. Diagnostics (Basel) 12:661. https:\/\/doi.org\/10.3390\/diagnostics12030661","journal-title":"Diagnostics (Basel)"},{"key":"7981_CR24","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1093\/ckj\/sfad238","volume":"16","author":"A Nordholm","year":"2023","unstructured":"Nordholm A, S\u00f8rensen IMH, Bjergfelt SS et al (2023) Plasma activin A rises with declining kidney function and is independently associated with mortality in patients with chronic kidney disease. Clin Kidney J 16:2712\u20132720. https:\/\/doi.org\/10.1093\/ckj\/sfad238","journal-title":"Clin Kidney J"},{"key":"7981_CR25","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1681\/ASN.2015030287","volume":"27","author":"WN Leonhard","year":"2016","unstructured":"Leonhard WN, Kunnen SJ, Plugge AJ et al (2016) Inhibition of activin signaling slows progression of polycystic kidney disease. J Am Soc Nephrol 27:3589\u20133599. https:\/\/doi.org\/10.1681\/ASN.2015030287","journal-title":"J Am Soc Nephrol"},{"key":"7981_CR26","doi-asserted-by":"publisher","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","volume":"285","author":"C Krause","year":"2010","unstructured":"Krause C, Korchynskyi O, de Rooij K et al (2010) Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614\u20131626. https:\/\/doi.org\/10.1074\/jbc.M110.153890","journal-title":"J Biol Chem"},{"key":"7981_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2215\/CJN.07670712","volume":"8","author":"S Pelletier","year":"2013","unstructured":"Pelletier S, Dubourg L, Carlier MC et al (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8:819\u2013823. https:\/\/doi.org\/10.2215\/CJN.07670712","journal-title":"Clin J Am Soc Nephrol"},{"key":"7981_CR28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2042","volume":"99","author":"M Kanbay","year":"2014","unstructured":"Kanbay M, Siriopol D, Saglam M et al (2014) Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 99:E1854. https:\/\/doi.org\/10.1210\/jc.2014-2042","journal-title":"J Clin Endocrinol Metab"},{"key":"7981_CR29","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1210\/en.2006-0848","volume":"148","author":"DS Perrien","year":"2007","unstructured":"Perrien DS, Akel NS, Edwards PK et al (2007) Inhibin a is an endocrine stimulator of bone mass and strength. Endocrinology 148:1654\u20131665. https:\/\/doi.org\/10.1210\/en.2006-0848","journal-title":"Endocrinology"},{"key":"7981_CR30","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1359\/jbmr.081208","volume":"24","author":"J Ruckle","year":"2009","unstructured":"Ruckle J, Jacobs M, Kramer W et al (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24:744\u2013752. https:\/\/doi.org\/10.1359\/jbmr.081208","journal-title":"J Bone Miner Res"},{"key":"7981_CR31","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.ekir.2019.08.001","volume":"4","author":"DW Coyne","year":"2019","unstructured":"Coyne DW, Singh HN, Smith WT et al (2019) Sotatercept safety and effects on hemoglobin, bone, and vascular calcification. Kidney Int Rep 4:1585\u20131597. https:\/\/doi.org\/10.1016\/j.ekir.2019.08.001","journal-title":"Kidney Int Rep"},{"key":"7981_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MNH.0000000000000798","volume":"31","author":"D Smout","year":"2022","unstructured":"Smout D, J\u00f8rgensen HS, Cavalier E et al (2022) Clinical utility of bone turnover markers in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 31:332\u2013338. https:\/\/doi.org\/10.1097\/MNH.0000000000000798","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"7981_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"HP Bhattoa","year":"2025","unstructured":"Bhattoa HP, Vasikaran S, Trifonidi I et al (2025) Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int 36:579\u2013608. https:\/\/doi.org\/10.1007\/s00198-025-07422-3","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07981-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07981-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07981-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:01:39Z","timestamp":1793048499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07981-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7981"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07981-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.N. has received personal fees from Torii Pharmaceutical. K.T. has received personal fees from Ono Pharmaceutical. H.K. has received personal fees from Kissei Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Sanwa Kagaku Kenkyusho and grants from Kyowa Kirin. The remaining authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}